Short Interest in Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) Decreases By 67.0%

Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) saw a large drop in short interest during the month of February. As of February 13th, there was short interest totaling 20,230 shares, a drop of 67.0% from the January 29th total of 61,344 shares. Based on an average daily volume of 466,445 shares, the short-interest ratio is presently 0.0 days. Currently, 3.0% of the company’s shares are sold short. Currently, 3.0% of the company’s shares are sold short. Based on an average daily volume of 466,445 shares, the short-interest ratio is presently 0.0 days.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on BDRX. Wall Street Zen raised shares of Biodexa Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Sunday, February 22nd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Biodexa Pharmaceuticals in a research note on Monday, December 29th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company has a consensus rating of “Sell”.

Institutional Trading of Biodexa Pharmaceuticals

A hedge fund recently bought a new stake in Biodexa Pharmaceuticals stock. Armistice Capital LLC bought a new position in Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 100,000 shares of the company’s stock, valued at approximately $227,000. Armistice Capital LLC owned 14.71% of Biodexa Pharmaceuticals at the end of the most recent quarter. Institutional investors own 17.51% of the company’s stock.

Biodexa Pharmaceuticals Price Performance

BDRX opened at $1.08 on Friday. Biodexa Pharmaceuticals has a 1 year low of $1.04 and a 1 year high of $44.40. The company’s 50 day simple moving average is $1.91 and its 200 day simple moving average is $4.66.

About Biodexa Pharmaceuticals

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease.